16492-13-0Relevant articles and documents
N-o-substituted phenyl benzamide-4-methylamino acridine compound as well as preparation method and application thereof
-
Paragraph 0024; 0025; 0036; 0037, (2020/05/05)
The invention discloses an N-o-substituted phenyl benzamide-4-methylamino acridine compound as well as a preparation method and application thereof. The compound is characterized in that the compoundis a compound with a structural formula shown as a formula I or pharmaceutically acceptable salt, ester or solvate thereof, wherein R1 is H, OCH3, OCH2CH3, F, Cl, Br, CF3, NO2 or straight-chain alkylwith a carbon atom number of 1-5; R2 is H, OCH3, OCH2CH3, F, Cl, Br, CF3, NO2 or straight-chain alkyl with a carbon atom number of 1 to 5; R3 is NH2, NHCH3, NHCH2CH3, OH, COOH, and SH, and R4 is H, OCH3 or linear alkyl with 1-5 carbon atoms and the like. The compound has the advantages that the compound can effectively inhibit DNA topoisomerase I, and proliferation of I-type HDAC and/or eukaryotictumor cells, and prevents and/or treats tumors.
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents
Zhang, Bin,Dou, Zhende,Xiong, Zheng,Wang, Ning,He, Shan,Yan, Xiaojun,Jin, Haixiao
, (2019/10/28)
A series of novel N-phenylbenzamide-4-methylamine acridine derivatives were designed and synthesized based initially on the structure of amsacrine (m-AMSA). Molecular docking suggested that the representative compound 9a had affinity for binding DNA topoisomerase (Topo) II, which was comparable with that of m-AMSA, and furthermore that 9a could have preferential interactions with Topo I. After synthesis of 9a and analogues 9b-9f, these were all tested in vitro and the synthesized compounds displayed potent antiproliferative activity against three different cancer cell lines (K562, CCRF-CEM and U937). Among them, compounds 9b, 9c and 9d exhibiting the highest activity with IC50 value ranging from 0.82 to 0.91 μM against CCRF-CEM cells. In addition, 9b and 9d also showed high antiproliferative activity against U937 cells, with IC50 values of 0.33 and 0.23 μM, respectively. The pharmacological mechanistic studies of these compounds were evaluated by Topo I/II inhibition, western blot assay and cell apoptosis detection. In summary, 9b effectively inhibited the activity of Topo I/II and induced DNA damage in CCRF-CEM cells and, moreover, significantly induced cell apoptosis in a concentration-dependent manner. These observations provide new information and guidance for the structural optimization of more novel acridine derivatives.
Synthesis and biological study of acridine-based imidazolium salts
Sharhan, Olla,Heidelberg, Thorsten,Hashim, Najiahah Mohd,Salman, Abbas Abdulameer,Ali, Hapipah Mohd,Jayash, Soher Nagi
, p. 38995 - 39004 (2018/12/02)
A new series of acridine based imidazolium salts was synthesized and evaluated for in vitro cytotoxicity against human cancer cell lines by an MTT assay. The synthesis applied a coupling of imidazoles with 9-chloroacridines, which originated from an Ullmann condensation of a 2-chloro-benzoic acid with an aniline. The target compounds were obtained in high yields. The DPPH assay indicated considerable antioxidant activity for target compounds with simple and short alkyl chains on the imidazole, while increasing chain length and the introduction of an additional π-electron system in most cases reduced the activity. All compounds exhibited low biotoxicity against non-cancerous cell lines, whereas a few compounds showed promising anticancer activity. Unlike for the reference drugs Tamoxifen and Paclitaxel, the anticancer activity of acridine imidazolium ions is specific for only selected cancer types. Reasonable fluorescent behaviour of the products provide potential for visualization of the distribution of active drugs in tissue.
